Close Menu

Biotech Rising

In 2014, the top six best-selling drugs will be biotech products, says EvaluatePharma, a healthcare analysis company. Of the top 100, they say biotech drugs will account for half. Evaulate predicts that the number one drug in five years will be Roche's Avastin, followed by Abbott's Humira, Roche's Rituxan, Wyeth's Enbrel, Sanofi-Aventis' Lantus, and Roche's Herceptin, according to Reuters.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.